King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...
Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...
Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership ...
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...
Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However ...
Researchers have revealed a novel mechanism by which the chromatin remodeler brahma-related gene 1 (Brg1) regulates Group 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback